NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: indacaterol/glycopyrrolate
Drug: indacaterol
Drug: placebo
Drug: glycopyrrolate

First Posted Date: 2007-11-14

Last Posted Date: 2012-11-30

Lead Sponsor: Novartis

Target Recruit Count: 257

Registration Number: NCT00558285

Locations: 🇹🇷
Novartis Investigator Site, Izmir, Turkey
🇫🇷
Novartis investigator site, Martigues, France
🇮🇹
Novartis Investigator site, Modena, Italy

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: COPD

Interventions: Drug: indacaterol
Drug: formoterol
Drug: placebo to formoterol
Drug: placebo to indacaterol
Drug: short acting β2- agonist

First Posted Date: 2007-11-14

Last Posted Date: 2013-01-18

Lead Sponsor: Novartis

Target Recruit Count: 568

Registration Number: NCT00557466

Locations: 🇬🇧
Novartis Investigator Site, Whitstable, United Kingdom
🇵🇱
Novartis Investigator site, Mrozy, Poland
🇩🇪
Novartis Investigator Site - 2 sites, Bonn, Germany

and more 2 locations

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: fluticasone propionate/salmeterol
Drug: indacaterol maleate / mometasone furoate
Drug: placebo to indacaterol/mometasone
Drug: placebo to fluticasone propionate/salmeterol

First Posted Date: 2007-11-14

Last Posted Date: 2013-03-21

Lead Sponsor: Novartis

Target Recruit Count: 37

Registration Number: NCT00557440

Locations: 🇩🇪
Novartis Investigator Site, Rostock, Germany
🇧🇪
Novartis Investigator site, Ghent, Belgium

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: indacaterol maleate/mometasone furoate
Drug: placebo to indacaterol maleate/mometasone furoate
Drug: fluticasone proprionate / salmeterol xinafoate

First Posted Date: 2007-11-12

Last Posted Date: 2013-04-22

Lead Sponsor: Novartis

Target Recruit Count: 31

Registration Number: NCT00556673

Locations: 🇩🇪
Novartis Investigator Site, Berlin, Germany

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Canakinumab

First Posted Date: 2007-11-07

Last Posted Date: 2021-07-09

Lead Sponsor: Novartis

Target Recruit Count: 115

Registration Number: NCT00554606

Locations: 🇹🇷
Novartis Investigator Site, Sihhiye/Ankara, Turkey

Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens

Not Applicable

Completed

Conditions: Screening for the Presence of HIV-1, RNA and HBV DNA in Blood Donations

Interventions: Device: Blood test

First Posted Date: 2007-11-01

Last Posted Date: 2021-02-21

Lead Sponsor: Novartis

Target Recruit Count: 10290

Registration Number: NCT00552214

Locations: 🇨🇳
Taipei Blood Center Taiwan Blood Service Foundation (TBSF), Taipei, Taiwan

Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
Drug: Rivastigmine patch (9.5 mg/day)
Drug: Rivastigmine capsules (6 mg to 12 mg/day)

First Posted Date: 2007-10-26

Last Posted Date: 2011-03-24

Lead Sponsor: Novartis

Target Recruit Count: 142

Registration Number: NCT00549601

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Spain

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Proteinuria
Microalbuminuria

Interventions: Drug: valsartan

First Posted Date: 2007-10-26

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 509

Registration Number: NCT00550095

Locations: 🇪🇬
Novartis Investigative Site ,, Cairo, Egypt

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan/amlodipine
Drug: Valsartan/hydrochlorothiazide (HCTZ)
Drug: Amlodipine/hydrochlorothiazide(HCTZ)
Drug: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)

First Posted Date: 2007-10-23

Last Posted Date: 2010-09-27

Lead Sponsor: Novartis

Target Recruit Count: 111

Registration Number: NCT00548067

Locations: 🇮🇳
Novartis investigative site, Mehasana, India
🇮🇳
Novartis Investigative site, Mangalore, India
🇮🇳
Novartis Investigative Site, Ahmedabad, India

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab

First Posted Date: 2007-10-18

Last Posted Date: 2010-09-02

Lead Sponsor: Novartis

Target Recruit Count: 32

Registration Number: NCT00546143

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany
🇿🇦
Novartis Investigative site, Bloemfontein, South Africa
🇩🇪
Novartis investigative site, Mainz, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy